Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Orthofix announces launch, first patient implants of fiberFUSE Strip » 07:32
07/28/21
07/28
07:32
07/28/21
07:32
OFIX

Orthofix

$38.10 /

-0.18 (-0.47%)

Orthofix announced the…

Orthofix announced the launch and first patient implants with the fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone. The fiberFUSE Strip is formulated as a convenient preformed bone-graft strip to enable optimized application for posterior cervical, posterior lumbar and degenerative spinal procedures.

ShowHide Related Items >><<
OFIX Orthofix
$38.10 /

-0.18 (-0.47%)

OFIX Orthofix
$38.10 /

-0.18 (-0.47%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$38.10 /

-0.18 (-0.47%)

Over a week ago
Hot Stocks
Publication data show 'high fusion rate' with PEMF therapy using Orthofix device » 07:15
07/12/21
07/12
07:15
07/12/21
07:15
OFIX

Orthofix

$40.21 /

+0.7 (+1.77%)

Orthofix Medical…

Orthofix Medical announced the publication of retrospective data evaluating fusion rates in patients receiving three- and four-level lumbar arthrodesis surgery who were treated adjunctively with the SpinalStim bone growth therapy device. Illustration of the Orthofix SpinalStim Bone Growth Therapy device for patients recovering from lumbar fusion surgery. Published in The International Journal of Spine Surgery, the study results show a 92.7% fusion rate in patients with and without risk factors such as diabetes, obesity, tobacco use, advanced age and osteoporosis - conditions that have been linked to higher rates of nonunion or bone healing complications. "We set out to evaluate the success rate of Pulsed Electromagnetic Field Stimulation, PEMF, therapy to demonstrate the efficacy when used as an adjunctive treatment in patients receiving three- and four-level lumbar fusion surgery," said Dr. Kris Radcliff, Professor of Orthopedic and Neurological Surgery at Thomas Jefferson University. "The fusion rate was very good across all patient types including those who were potentially at high risk of fusion failure. These results reconfirm the benefit PEMF therapy can provide patients when used after multi-level lumbar fusion surgery."

ShowHide Related Items >><<
OFIX Orthofix
$40.21 /

+0.7 (+1.77%)

OFIX Orthofix
$40.21 /

+0.7 (+1.77%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$40.21 /

+0.7 (+1.77%)

Over a month ago
Hot Stocks
Orthofix launches 1st patient implant of 3d printed spacer system FORZA » 07:07
06/29/21
06/29
07:07
06/29/21
07:07
OFIX

Orthofix

$40.23 /

-1.81 (-4.31%)

Orthofix Medical…

Orthofix Medical announced the U.S. launch and first patient implant of the FORZA Ti PLIF Spacer System. Developed to enhance Posterior Lumbar Interbody Fusion procedures, the 3D-printed FORZA Ti Spacer with Nanovate Technology is a titanium lumbar interbody device featuring an optimized design, porosity and surface that allows bone to grow into and through the spacer. "Posterior lumbar interbody fusion involves inserting an interbody device between the vertebrae during a spinal fusion surgery to help relieve pressure on nerves and hold the vertebrae in place while fusion occurs," said Dr. Joel Siegal, a neurosurgeon at St. Vincent Charity Medical Center in Cleveland, Ohio, who performed the first implant procedure. "Being able to maximize bone ingrowth is critical to the success of the fusion process. The large opening for packing bone grafting materials and the 3D-printed titanium endplates of the FORZA Ti Spacer are well designed to aid in our goal of maximizing bone ingrowth to aid fusion."

ShowHide Related Items >><<
OFIX Orthofix
$40.23 /

-1.81 (-4.31%)

OFIX Orthofix
$40.23 /

-1.81 (-4.31%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$40.23 /

-1.81 (-4.31%)

Conference/Events
Orthofix management to meet virtually with Sidoti » 04:55
05/19/21
05/19
04:55
05/19/21
04:55
OFIX

Orthofix

$41.02 /

-0.05 (-0.12%)

Virtual Meeting to be…

Virtual Meeting to be held on May 19 hosted by Sidoti.

ShowHide Related Items >><<
OFIX Orthofix
$41.02 /

-0.05 (-0.12%)

OFIX Orthofix
$41.02 /

-0.05 (-0.12%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$41.02 /

-0.05 (-0.12%)

Conference/Events
Orthofix management to meet virtually with Sidoti » 10:49
05/18/21
05/18
10:49
05/18/21
10:49
OFIX

Orthofix

$41.40 /

+0.33 (+0.80%)

Virtual Meeting to be…

Virtual Meeting to be held on May 19 hosted by Sidoti.

ShowHide Related Items >><<
OFIX Orthofix
$41.40 /

+0.33 (+0.80%)

OFIX Orthofix
$41.40 /

+0.33 (+0.80%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$41.40 /

+0.33 (+0.80%)

Hot Stocks
Orthofix announces US and European full market launch of OSCAR PRO system » 07:25
05/17/21
05/17
07:25
05/17/21
07:25
OFIX

Orthofix

$42.55 /

+0.605 (+1.44%)

Orthofix Medical…

Orthofix Medical announced the U.S. and European full market launch of the OSCAR PRO Ultrasonic Arthroplasty Revision System. Designed to reduce the challenges associated with revising failed cemented arthroplasties, the OSCAR PRO is an ultrasonic surgical system that aids in the removal of cement during complex joint revision surgeries. OSCAR PRO system for arthroplasty procedures and osteotomies.The OSCAR PRO system is a fourth generation product from the OSCAR line that has been the gold standard in assisting with complex joint revision surgeries since 1990," said Orthofix President of Global Orthopedics Paul Gonsalves. "The technology is well accepted and has been used successfully for decades in removing cement total joint arthroplasties and aiding cementless prosthesis removal. We are pleased to continue to bring new innovations to the market to assist surgeons in performing these often challenging procedures."

ShowHide Related Items >><<
OFIX Orthofix
$42.55 /

+0.605 (+1.44%)

OFIX Orthofix
$42.55 /

+0.605 (+1.44%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$42.55 /

+0.605 (+1.44%)

Hot Stocks
Orthofix receives FDA clearance for OrthoNext digital platform » 07:14
05/10/21
05/10
07:14
05/10/21
07:14
OFIX

Orthofix

$44.13 /

+0.48 (+1.10%)

Orthofix announced…

Orthofix announced expansion of its pediatric offerings with the FDA 510(k) clearance of the OrthoNext digital platform, the only software tool in the market for deformity analysis and preoperative planning for pediatric orthopedic procedures.

ShowHide Related Items >><<
OFIX Orthofix
$44.13 /

+0.48 (+1.10%)

OFIX Orthofix
$44.13 /

+0.48 (+1.10%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$44.13 /

+0.48 (+1.10%)

Over a quarter ago
Earnings
Orthofix reports Q1 adjusted EPS 17c, consensus 2c » 07:20
04/30/21
04/30
07:20
04/30/21
07:20
OFIX

Orthofix

$44.81 /

+0.85 (+1.93%)

Reports Q1 revenue…

Reports Q1 revenue $105.59M, consensus $95.61M. "We are excited about the topline performance of the business during the first quarter, particularly as we continued to contend with the headwinds of the global pandemic and the added challenges of the recent severe winter weather-related disruption," said Orthofix president and CEO Jon Serbousek. "We are pleased with the positive revenue impact from initiatives we put into place in 2020, including a focus on new product introductions and the development of our U.S. commercial channel. Both our M6-C(TM) artificial cervical disc and the FITBONE(R) lengthening nail delivered during the quarter, and we saw positive revenue contributions from increased product adoption driven by new strategic distribution partners."

ShowHide Related Items >><<
OFIX Orthofix
$44.81 /

+0.85 (+1.93%)

OFIX Orthofix
$44.81 /

+0.85 (+1.93%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$44.81 /

+0.85 (+1.93%)

Hot Stocks
Orthofix announces US license for IGEA's bone and joint stimulation devices » 07:31
04/28/21
04/28
07:31
04/28/21
07:31
OFIX

Orthofix

$43.79 /

-0.45 (-1.02%)

Orthofix Medical…

Orthofix Medical announced they have entered into an exclusive license agreement to commercialize the innovative portfolio of Italy-based IGEA S.p.A's bone, cartilage and soft tissue stimulation products in the U.S and Canada. Under terms of this agreement, Orthofix has the rights to pursue U.S Food and Drug Administration approvals and commercialization of IGEA's platform of orthopedic products, which are not currently available in the U.S. These products, which will be marketed under the Orthofix brand, will expand Orthofix's bone growth therapies portfolio of Pulsed Electromagnetic Field products with additional treatment modalities and indications such as Low-Intensity Pulsed Ultrasound and Capacitive Coupling for fracture management. The license also includes innovative, new technology applications designed to address joint inflammation, pain, and cartilage protection. "Orthofix is the U.S. market leader with our PEMF technology bone growth stimulation systems indicated for post-operative spinal fusions and treating bone fractures that have not healed after surgery, and IGEA is the European market and technology leader for bone and joint stimulation," said Orthofix President and Chief Executive Officer Jon Serbousek. "Combined, these portfolios will enable us to offer physicians and patients additional treatment solutions for fracture management and complement our pursuit of new indications for managing soft tissue and joint health such as our ongoing rotator cuff repair IDE clinical study." Founded 40 years ago at the University of Modena, Italy, IGEA is a leader in the manufacturing and distribution of bone and joint cartilage stimulation systems which include stimulation modalities of LIPUS, PEMF and capacitive coupling. Outside of the U.S. more than 20,000 patients are treated every year with their products. "As a company with a long history of treating patients in Europe, we are excited to enter into this agreement that will expand the availability of our bone and joint cartilage systems to patients in the U.S.,"

ShowHide Related Items >><<
OFIX Orthofix
$43.79 /

-0.45 (-1.02%)

OFIX Orthofix
$43.79 /

-0.45 (-1.02%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$43.79 /

-0.45 (-1.02%)

Hot Stocks
Orthofix announces FDA clearance, first patient implant of Forza Ti TLIF » 07:17
04/22/21
04/22
07:17
04/22/21
07:17
OFIX

Orthofix

$45.15 /

+1.09 (+2.47%)

Orthofix announced the…

Orthofix announced the FDA 510 clearance and first patient implant of the Forza Ti TLIF Spacer System. Developed to help optimize Transforaminal Lumbar Interbody Fusion, or TLIF, procedures, the FORZA Ti Spacer with Nanovate Technology is a titanium 3D-printed interbody featuring an optimized design, porosity and surface that allows bone to grow into and through the spacer. Interbody implants are spacers that surgeons insert between the vertebrae during spinal fusion surgery to help relieve pressure on nerves and hold the vertebrae in place while fusion occurs.

ShowHide Related Items >><<
OFIX Orthofix
$45.15 /

+1.09 (+2.47%)

OFIX Orthofix
$45.15 /

+1.09 (+2.47%)

10/19/20 Stifel
Orthofix initiated with a Hold at Stifel
OFIX Orthofix
$45.15 /

+1.09 (+2.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.